Omnicare Clinical Research announces the re-branding of the company under the name Theorem Clinical Research. The brand launch marks the final step in the CRO's separation from its former parent company in a deal that was finalized this spring.
Nautic Partners, LLC, a private equity firm based in Providence, R.I., acquired the CRO in a transaction publicized in April. The signing of the deal not only made official the separation of Omnicare Clinical Research from former parent company, Omnicare, Inc., it accomplished the company‟s most visible step in achieving the long-identified goal: to stand on its own and deliver results the way that clients need.
Now, under the new name, Theorem Clinical Research will bring its more than two decades of experience and industry leadership to manage complex trials. With approximately 1,000 dedicated professionals and locations around the globe, Theorem Clinical Research will continue to provide full-service clinical trial management, with a continued focus on its core CRO (Early Phase, Phase II/III, Late Phase) and its specialized business units:
· Pharmaceutics
· Medical Device
· Technical Services (Biometrics & Clinical Data Management)
“The re-branding of the company is not something that happened overnight,” says Dr. James Pusey, President & CEO, Theorem Clinical Research. “This is 25 years in the making. We are now able to be more agile and efficient since we are now in the driver‟s seat of our own company. We strive to be able to work the way our clients do; from our specialized business units to our 32 locations, Theorem Clinical Research (aims) to give clients exactly what they need.”
Theorem will be at the 47th Annual Drug Information Association (DIA) Meeting, June 19-23 in Chicago to kick-off the new brand. Visit them at Booth 529.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.